Disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Nitin R Desai has submitted the disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 199228-02-2015
28-02-2015
Investor Presentaiton
Cadila Healthcare Ltd has submitted to BSE a copy of Presentation, proposed to be made to the investors at the Investors' Conference at Mumbai on February 24, 2015 to bring to the notice of members of exchange and investors at large.23-02-2015
Zydus completes single rising dose Phase I studies for its oral HIF inhibitor, ZYAN1 for treating Anemia and initiates multiple dosing studies
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 16, 2015 titled "Zydus completes single rising dose Phase I studies for its oral HIF inhibitor, ZYAN1 for treating Anemia and initiates multiple dosing studies".16-02-2015
Results Press Release
Cadila Healthcare Ltd has submitted to BSE a copy of Results Press Release for the period ended December 31, 2014.10-02-2015
Announces Q3 results & Limited Review Report for the Quarter ended December 31, 2014
Cadila Healthcare Ltd has announced the following results for the quarter ended December 31, 2014:The Unaudited Standalone results for the Quarter ended December 31, 2014The Company has posted a net profit of Rs. 3611.60 million for the quarter ended December 31, 2014 as compared to Rs. 1949.30 million for the quarter ended December 31, 2013. Total Income has increased from Rs. 10874.80 million for the quarter ended December 31, 2013...10-02-2015
Zydus announces data presentations on Saroglitazar for treating NASH, a liver disease, at the 2015 Keystone Symposia Conference on Liver Metabolism and Nonalcoholic Fatty Liver Disease (NAFLD) in British Columbia, Canada
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 06, 2015 titled "Zydus announces data presentations on Saroglitazar for treating NASH, a liver disease, at the 2015 Keystone Symposia Conference on Liver Metabolism and Nonalcoholic Fatty Liver Disease (NAFLD) in British Columbia, Canada".06-02-2015
The Ramanbhai Foundation 7th International Research Symposium Advances in New Drug Discovery and Development gets underway
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 02, 2015, titled "The Ramanbhai Foundation 7th International Research Symposium Advances in New Drug Discovery and Development gets underway".02-02-2015
Q3 results on Feb 10, 2015
Cadila Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 10, 2015, inter alia, to consider & approve the unaudited financial results for the quarter and nine months ended on December 31, 2014 (Q3).Further, as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 1992, the Trading Window will remain...20-01-2015
Cadila Healthcare Ltd reply to clarification sought by the exchange
The Exchange had sought clarification from Cadila Healthcare Ltd with respect to news appearing in Business Standard on January 09, 2015 titled "Cadila recalls 19,536 bottles of cough treatment drug in US."Cadila Healthcare Ltd replied stating "The recall by our US subsidiary was voluntary and a class-II type recall. The Company does not envisage any material impact".09-01-2015
Clarification sought from Cadila Healthcare Ltd
The Exchange has sought clarification from Cadila Healthcare Ltd with respect to news article appearing in Business Standard on January 09, 2015 titled "Cadila recalls 19,536 bottles of cough treatment drug in US."The reply is awaited.09-01-2015